Is the mechanism of action of Seladelpar related to PPAR agonists?

Seladelpar is a selective peroxisome proliferator-activated receptor delta (PPARdelta) agonist. Its mechanism of action is closely related to the PPAR family receptors, especially the PPARδ subtype. PPARReceptor is a type of nuclear transcription factor that participates in the regulation of lipid metabolism, inflammatory response and energy homeostasis by regulating gene expression. Siladepa exerts its metabolism-regulating and anti-inflammatory effects by activating PPARδ, thereby achieving the effect of treating diseases.

Specifically, after Siladepa activatesPPARδ, it promotes fatty acid oxidation and energy consumption and improves abnormal lipid metabolism. In addition, activating PPARδ can also inhibit the activation of inflammatory cells and the production of pro-inflammatory factors, reducing chronic inflammatory reactions. These effects make Siladepa show good therapeutic potential in the treatment of hepatobiliary diseases such as primary biliary cholangitis (PBC), especially improving liver function and reducing liver inflammation.

Siladepa acts as a PPAR agonist, with PPARalpha and PPAR γ agonists such as fenofibrate are more selective than thiazolidinediones. They target the activation of PPARδ, resulting in relatively few side effects and the advantage of strong specificity. This selectivity reduces interference with other PPAR subtypes and helps improve the safety and tolerability of the treatment.

In short, the mechanism of action of Siladepa is indeed closely related to the PPAR agonist. By selectively activating the PPARdelta receptor, it regulates lipid metabolism and inflammatory response, thereby improving the pathological state of liver disease. In the future, with the advancement of more clinical studies, the application prospects of Siladepa in metabolic and inflammatory diseases will be broader.

Reference materials:https://www.drugs.com/donanemab.html